Department of Internal medicine, Division of Infectious diseases, Detroit Medical Center/Wayne State University, Detroit, MI, USA.
Department of Internal Medicine, Division of Infectious diseases, Wayne State University, Detroit, MI, USA.
Expert Opin Pharmacother. 2021 Oct;22(15):2071-2078. doi: 10.1080/14656566.2021.1940134. Epub 2021 Jun 21.
Azoles are the first-line antifungal agents used for the treatment of infection. There is an increasing concern for azole resistance all over the world mainly from agricultural fungicide use. Choosing safe and effective antifungal regimens has become a challenge.
Here, the authors review the epidemiology, mechanisms, and detection of azole resistance along with management options for azole-resistant infection, including new antifungal agents under development.
Routine global epidemiological surveillance is required to understand azole resistance prevalence. Azole-resistant infections are associated with high mortality. No good therapeutic options are currently available. High index of suspicion of resistance is required if a patient is not responding to 4-7 days of azole therapy, particularly in the areas of resistance. Susceptibility testing for is not routinely available in many parts of the world, which makes it difficult to diagnose azole resistance in infection. There are several new antifungal classes with novel mechanisms of action; clinical trials are ongoing.
唑类药物是治疗 感染的一线抗真菌药物。由于农业杀菌剂的广泛使用,世界各地对唑类耐药性的担忧日益增加。选择安全有效的抗真菌治疗方案已成为一项挑战。
本文作者回顾了唑类耐药性的流行病学、机制和检测,以及唑类耐药性 感染的管理选择,包括正在开发的新型抗真菌药物。
需要进行常规的全球流行病学监测,以了解唑类耐药性的流行情况。唑类耐药性 感染与高死亡率相关。目前尚无有效的治疗选择。如果患者对 4-7 天的唑类治疗没有反应,特别是在耐药性地区,就需要高度怀疑存在耐药性。在世界上许多地区,并不常规进行 的药敏试验,这使得在 感染中诊断唑类耐药性变得困难。有几种具有新型作用机制的新型抗真菌药物类别;临床试验正在进行中。